D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

The striatum, which is the major component of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. Severe movement disorders result from the loss of striatal dopamine in patients with Parkinson's disease. Rats with lesions of the nigrostriatal dopamine pathway caused by 6-hydroxydopamine (6-OHDA) serve as a model for Parkinson's disease and show alterations in gene expression in the two major output systems of the striatum to the globus pallidus and substantia nigra. Striatopallidal neurons show a 6-OHDA-induced elevation in their specific expression of messenger RNAs (mRNAs) encoding the D2 dopamine receptor and enkephalin, which is reversed by subsequent continuous treatment with the D2 agonist quinpirole. Conversely, striatonigral neurons show a 6-OHDA-induced reduction in their specific expression of mRNAs encoding the D1 dopamine receptor and substance P, which is reversed by subsequent daily injections of the D1 agonist SKF-38393. This treatment also increases dynorphin mRNA in striatonigral neurons. Thus, the differential effects of dopamine on striatonigral and striatopallidal neurons are mediated by their specific expression of D1 and D2 dopamine receptor subtypes, respectively.

[1]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[2]  G. Racagni,et al.  Projections of substance P containing neurons from neostriatum to substantia nigra , 1977, Brain Research.

[3]  M. Brownstein,et al.  On the origin of substance P and glutamic acid decarboxylase (GAD) in the substantia nigra , 1977, Brain Research.

[4]  H. Y. Yang,et al.  Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs , 1978, Neuropharmacology.

[5]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[6]  P. Petrusz,et al.  The immunocytochemical localization of enkephalin in the central nervous system of the rat , 1981, The Journal of comparative neurology.

[7]  W. Lovenberg,et al.  Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems. , 1981, The Journal of pharmacology and experimental therapeutics.

[8]  W. Lovenberg,et al.  Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist , 1981, Neuropharmacology.

[9]  D. Sibley,et al.  The classification of dopamine receptors: relationship to radioligand binding. , 1983, Annual review of neuroscience.

[10]  H. Kita,et al.  Pallidal inputs to subthalamus: Intracellular analysis , 1983, Brain Research.

[11]  R. Wurtz,et al.  Visual and oculomotor functions of monkey substantia nigra pars reticulata. IV. Relation of substantia nigra to superior colliculus. , 1983, Journal of neurophysiology.

[12]  T. F. Freund,et al.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines , 1984, Neuroscience.

[13]  J. Deniau,et al.  Disinhibition as a basic process in the expression of striatal functions. I. The striato-nigral influence on tecto-spinal/tecto-diencephalic neurons , 1985, Brain Research.

[14]  J. Penney,et al.  γ‐Aminobutyric Acid and Benzodiazepine Receptor Changes Induced by Unilateral 6‐Hydroxydopamine Lesions of the Medial Forebrain Bundle , 1985, Journal of neurochemistry.

[15]  L. Schmued,et al.  Fluoro-gold: a new fluorescent retrograde axonal tracer with numerous unique properties , 1986, Brain Research.

[16]  T. Bonner,et al.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. M. Beckstead,et al.  Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat , 1986, Neuroscience.

[18]  G. Hanson,et al.  Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors. , 1987, European journal of pharmacology.

[19]  J. McGinty,et al.  Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway. , 1987, The Journal of pharmacology and experimental therapeutics.

[20]  H. Groenewegen,et al.  Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions , 1987, Brain Research.

[21]  R. M. Beckstead.  Association of dopamine d, and d2 receptors with specific cellular elements in the basal ganglia of the cat: The uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons , 1988, Neuroscience.

[22]  H. Kita,et al.  Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations , 1988, Brain Research.

[23]  J. McGinty,et al.  Regulation of the metabolism of striatal dynorphin by the dopaminergic system. , 1988, The Journal of pharmacology and experimental therapeutics.

[24]  C. Gerfen,et al.  Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study , 1988, Brain Research.

[25]  C. Auffray,et al.  Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons , 1988, Brain Research.

[26]  C. Gerfen,et al.  Multiple D2 dopamine receptors produced by alternative RNA splicing , 1989, Nature.

[27]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[28]  R. G. Robertson,et al.  Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1989, Neuroscience.

[29]  E. Richfield,et al.  Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system , 1989, Neuroscience.

[30]  B. Bloch,et al.  Dopamine receptor gene expression by enkephalin neurons in rat forebrain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. McGinty,et al.  Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes , 1990, Brain Research.

[32]  P. Robledo,et al.  Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data , 1990, Brain Research.

[33]  H. Fibiger,et al.  Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos , 1990, Brain Research.

[34]  C. Gerfen,et al.  Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Wilson,et al.  Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.